TY - JOUR
T1 - Role of circulating lipid abnormalities in chronic renal allograft rejection
AU - Kasiske, Bertram L.
PY - 1999/12/1
Y1 - 1999/12/1
N2 - The evidence that circulating lipid abnormalities may play a role in the pathogenesis of chronic renal allograft rejection is tantalizing but circumstantial. In animal models of cardiac and aorta allograft rejection, lipogenic diets accelerate vascular injury, and treatment with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors reduce vascular injury. Histological studies have demonstrated foam cells and apolipoprotein deposits in the intima of arteries from chronically rejecting human kidneys. Observational studies have found correlations between plasma lipid levels and both acute and chronic rejection. The association between lipid levels and acute rejection in cyclosporine A (CsA)-treated renal transplant recipients suggests the possibility that plasma lipids may influence the immunosuppressive effects of CsA by modulating the lipoprotein-free levels of CsA. If true, such an effect could also explain the results of recent controlled trials showing that HMG-CoA reductase inhibitors reduced graft coronary artery disease and that they prolonged survival in heart transplant recipients. In any case, the hypothesis that circulating lipid abnormalities contribute to chronic renal allograft rejection deserves further testing in well-designed, clinical trials.
AB - The evidence that circulating lipid abnormalities may play a role in the pathogenesis of chronic renal allograft rejection is tantalizing but circumstantial. In animal models of cardiac and aorta allograft rejection, lipogenic diets accelerate vascular injury, and treatment with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors reduce vascular injury. Histological studies have demonstrated foam cells and apolipoprotein deposits in the intima of arteries from chronically rejecting human kidneys. Observational studies have found correlations between plasma lipid levels and both acute and chronic rejection. The association between lipid levels and acute rejection in cyclosporine A (CsA)-treated renal transplant recipients suggests the possibility that plasma lipids may influence the immunosuppressive effects of CsA by modulating the lipoprotein-free levels of CsA. If true, such an effect could also explain the results of recent controlled trials showing that HMG-CoA reductase inhibitors reduced graft coronary artery disease and that they prolonged survival in heart transplant recipients. In any case, the hypothesis that circulating lipid abnormalities contribute to chronic renal allograft rejection deserves further testing in well-designed, clinical trials.
KW - Chronic allograft rejection
KW - HMG co-enzyme A reductase inhibitors
KW - Hypcrcholesterolemia
KW - Hyperlipidemia
KW - Transplantation
UR - http://www.scopus.com/inward/record.url?scp=0033050557&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033050557&partnerID=8YFLogxK
M3 - Article
C2 - 10412732
AN - SCOPUS:0033050557
SN - 0098-6577
VL - 56
JO - Kidney International, Supplement
JF - Kidney International, Supplement
IS - 71
ER -